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Tuberculosis (TB) was explicitly recognized as a major global public health problem in the
early 1990s and, if it is to be eliminated, it is essential that every country organize control
activities in line with its own epidemiological situation.
Portugal still remains among the countries with intermediate incidence, with 2756 cases
of TB diagnosed in 2009. The incidence of multidrug-resistant (MDR) TB has been decreas-
ing, representing an average of 1.7% of the total number of TB cases, with about 25% of
extensively drug-resistant (XDR) TB, and with more than two thirds residing in the region
of Lisbon and Vale do Tejo (LVT).
The aim of this study is to evaluate risk factors and treatment outcomes associated with
MDR and XDR-TB in LVT during the time period of 2008–2010. In 50 (2.4%) out of 2093 cul-
ture-positive TB cases from patients diagnosed in the LVT region, Mycobacterium tuberculosis
(MTB) isolates were identified as MDR-TB; 12 (24%) met the criteria for XDR-TB. It was noted
that HIV-positive status and retreatment cases are still closely associated with drug-resis-
tant TB. Although the WHO target of about 75% treatment success rates for MDR-TB was
not yet achieved, extensive drug susceptibility testing and the availability of second- and
third-line drugs under strictly supervised treatment conditions permitted relatively good
treatment success rates in MDR and XDR-TB cases in Lisbon.
 2012 Asian-African Society for Mycobacteriology. All rights reserved.Introduction
Tuberculosis (TB) is a serious bacterial disease, which most
commonly affects the lungs, and it is the leading cause of
death from a curable infectious disease.
In the European Union (EU), TB incidence rates are among
the lowest in the world. However, the epidemiological pattern
varies considerably from country to country, with some coun-
tries showing steady progress towards eliminating the dis-
ease, while others still face unacceptably high incidence
rates. In all countries, control efforts have to deal with the
challenges of multidrug-resistant (MDR) and extensively-African Society for Myco
Patoge´nese Molecular, U
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. Portugal).drug-resistant (XDR) TB, co-infection with human immuno-
deficiency virus (HIV) infection, and the concentration of
cases in vulnerable groups.
In 2009, there were approximately 9.4 million TB cases in
the whole world, i.e., 139 new cases per 100,000 inhabitants,
with a mortality of 1.3 million people (20/100,000). Most cases
(85%) still occur in Asia (50%) and Africa (30%). In the EU,
79,665 TB cases—new and retreatment cases—were reported,
giving an overall notification rate of 15.8 per 100,000 popula-
tion and showing an annual decrease of 3.8% [1]. Although
great progress has been made in the last 15 years since the
implementation of the Directly Observed Treatment,bacteriology. All rights reserved.
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fined as TB with resistance to, at least, both isoniazid and rif-
ampicin, poses a serious challenge for TB control; 23 out of 30
countries of the European Economic Area (EEA) reported
MDR-TB cases, with the Baltic States, Spain, Romania and
Italy reporting 50 or more cases. The overall proportion of
MDR-TB amongst new and retreatment cases was 5.3% (rang-
ing from 0% to over 50% in Lithuania or Estonia) [1–3]. XDR-TB
was reported in 15 European countries. In 2009, 66 XDR-TB
cases (MDR-TB with additional resistance to a fluoroquino-
lone and one or more of the second-line injectable drugs)
were reported, with an increase from 6.1% to 7.0% since
2007 [1], and are supposedly associated with worse treatment
outcomes than those with MDR-TB [4–7].
In 2009, in Portugal, 2756 TB cases were diagnosed, includ-
ing 2565 new cases, i.e., 24.1/100,000 population. Although it
still remains among the countries with intermediate inci-
dence—the only one in Western Europe—this represents a
reduction of 8% compared with the incidence rate in 2008,
which is a higher reduction than the median in the EU, and
which continues the evolution towards a consistent decrease
since 2002 [3]. The incidence of MDR-TB has also been
decreasing, representing an average of 1.7% of the total num-
ber of TB cases in 2009 (1.2% in new cases and 7.5% in retreat-
ments). It is comparable to the median in the EU and is
virtually confined to the metropolitan areas of Porto (the sec-
ond largest city of Portugal) and, mainly, Lisbon. The fact that
it takes longer to treat raises the number of prevalent cases:
in December 2009, the prevalence of MDR-TB was 63 cases,
24% of which were also XDR, and more than two thirds
(68%) of the cases resided in LVT [3].
HIV-positive status is the major risk factor associated with
TB. It is an important programmatic objective that HIV testing
is performed on all TB patients, and there has been a progres-
sive increase of its coverage. In 2009, the test covered 87% of
the TB cases, confirming the prevalence of infection in 15%
of cases (391 cases) which represents a decrease of 45% in
the last 10 years. However, Portugal has the highest preva-
lence of TB-HIV throughout the EU, with an average of 2.3%
of the cases, most of them (81%) concentrated in the metro-
politan areas of Lisbon and Porto [1,3].
Since 2000, TB surveillance data for Portugal is reported
annually to the National TB Programme (NTP) through its
Intrinsic Surveillance System, SVIG-TB; however, the inten-
tion of this research is to assess the prevalence and risk fac-
tors associated with MDR and XDR-TB.Materials and methods
Study design and data collection
All TB cases diagnosed in LVT between 2008 and 2010 were
analysed. TB patient’s data was collected on a standardized
form by the physician [8,9] and reported to SVIG-TB. The re-
cords included various information on each patient, including
age, gender and country of origin, HIV-seropositivity status,
history of previous treatment, Mycobacterium tuberculosis
drug-resistance profile, treatment regimen and outcomes.Laboratory drug susceptibility testing
Drug susceptibility testing (DST) for first-line anti-TB drugs
(isoniazid, rifampicin, ethambutol, pyrazinamide and strepto-
mycin) and for second-line drugs (ethionamide, amikacin,
capreomycin, p-aminosalicylic acid, cycloserine and fluoro-
quinolones–ofloxacin and ciprofloxacin for the study period)
or third-line drugs (linezolid) was performed by quality-as-
sured laboratories. The BACTEC MGIT 960 (Becton Dickinson
Diagnostic Systems, Sparks, MD, USA) was used for DST of
first-line drugs and BACTEC MGIT 960 or the proportion meth-
od on Lowenstein–Jensen medium, or both, were used for DST
of second- and third-line drugs.
Definitions
MDR-TB was defined as resistance to at least both isoniazid
and rifampicin; XDR TB was defined as MDR-TB with addi-
tional resistance to a fluoroquinolone, and at least one of
the injectable drugs capreomycin, kanamycin, or amikacin
[10,11]. Only cases with DST performed before initiating treat-
ment or before 1 month of treatment were considered.
A new TB case was defined as a patient who had never had
treatment for TB or who had received anti-tuberculosis drugs
for less than 1 month (excluding prophylactic purposes); and
retreatment cases were defined as patients who had a prior
history of treatment with anti-tuberculosis drugs for more
than 1 month (curative purposes) [12].
For the outcomes evaluation, the cohort with 24 months’
treatment duration, i.e., the 2008 MDR-TB cases, was consid-
ered. A patient was classified as ‘‘cured’’ when he or she had
completed treatment according to the country protocol and
had been consistently culture-negative (with at least five re-
sults) for the last 12 months of treatment; ‘‘treatment com-
pleted’’ when he or she had completed treatment according
to the country protocol, but did not meet the definition for
cure or treatment failure or bacteriologic results were missing
(i.e.,<5 cultures were performed in the final 12 months of ther-
apy) [13].
Statistical analysis
In the statistical analysis, demographic, socio-behavioural
and clinical characteristics of the patients were included. Uni-
variable analysis was performed to assess risk factors for
MDR-/XDR-TB. Statistical parameters were compared by
using fisher exact test or qui-squared test for categorical data
and t-test for numeric data, whenever appropriate. A p-value
60.05 was defined as statistically significant.Results
Among 2093 culture-confirmed TB cases in the LVT region in
the 3-year period 2008–2010, 50 (2.4%) M. tuberculosis isolates
were resistant in vitro to at least isoniazid and rifampicin. Of
these cases, 12 (24%) were also XDR-TB. Demographic and
clinical characteristics of the studied population are de-
scribed in Tables 1 and 2.
Table 1 – Demographic, socio-behavioural and clinical characteristics of the TB patients in the LVT region from 2008 to 2010.
Variables Category TB patients n = 2093 p Value IC (95%)
MDR-TB
n = 50
Non MDR-TB
n = 2043
Demographic characteristics
Gender, nr (%) Male 39 (78.0) 1358 (66.5) 0.096 0 to 0.23
Female 11 (22.0) 685 (33.5)
Age groups, year (%) 0–14 – 22 (1.1) –
15–44 26 (52.0) 1129 (55.3) 0.668 0.17 to 0.11
45–64 18 (36.0) 554 (27.1) 0.198 0.05 to 0.22
65+ 6 (12.0) 338 (16.5) 0.445 0.14 to 0.05
Mean age ± SD 42 ± 16 45 ± 18 –
Country of birth, nr (%) Portugal 28 (56.0) 1486 (72.7) 0.015 0.31 to 0.03
Others 22 (44.0) 557 (27.3)
Social-behaviour characteristics
Homelessness, nr (%) 1 (2.0) 52 (2.5) 1.000 0.04 to 0.03
Alcoholism, nr (%) 12 (24.0) 293 (14.3) 0.066 0.02 to 0.22
IV addition, nr (%) 5 (10.0) 243 (11.9) 0.827 0.10 to 0.07
Incarceration, nr (%) 2 (4.0) 40 (2.0) 0.265 0.03 to 0.08
Clinical characteristics
HIV positive, nr (%) 16 (32.0) 411 (20.1) 0.050 -0.01 to 0.25
Previous treatment, nr (%) 15 (30.0) 147 (7.2) <0.0001 0.10 to 0.36
TB presentation, nr (%) Pulmonary 46 (92.0) 1573 (77.0) 0.010 0.07 to 0.23
Extrapulmonary 4 (8.0) 470 (23.0)
Table 2 – Demographic, socio-behavioural and clinical characteristics of the XDR-TB patients in the LVT region from 2008 to
2010.
Variables Category MDR-TB n = 50 p Value IC (95%)
XDR-TB
n = 12
Non XDR-TB
n = 38
Demographic characteristics
Gender, nr (%) Male 10 (83.3) 29 (76.3) 1.000 0.19 to 0.33
Female 2 (16.7) 9 (27.7)
Age groups, year (%) 0–14 – – – –
15–44 6 (50.0) 20 (52.6) 1.000 0.36 to 0.31
45–64 6 (50.0) 12 (31.6) 0.309 0.14 to 0.51
65+ 0 6 (15.8) 0.314 –
Mean age ± SD 42 ± 16 44 ± 17 0.721 13.20 to 9.20
Country of birth, nr (%) Portugal 8 (66.7) 20 (52.6) 0.512 0.17 to 0.46
Others 4 (33.3) 18 (47.4)
Social-behaviour characteristics
Homelessness, nr (%) 0 1 (2.6) 1.000 –
Alcoholism, nr (%) 4 (33.3) 8 (21.1) 0.448 0.18 to 0.43
IV addition, nr (%) 1 (8.3) 4 (10.5) 1.000 0.21 to 0.17
Incarceration, nr (%) 2 (16.7) 0 0.054 0.05 to 0.38
Clinical characteristics
HIV positive, nr (%) 4 (33.3) 12 (31.6) 1.000 0.30 to 0.33
Previous treatment, nr (%) 6 (50.0) 9 (23.7) 0.084 0.01 to 0.21
TB presentation, nr (%) Pulmonary 12 (100.0) 34 (89.5) 0.560 0.01 to 0.21
Extrapulmonary 0 4 (10.5)
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(median age 44 ± 17 and 42 ± 16 years old, respectively) and
male (78.0% and 83.3%, respectively). Almost half of the
MDR-TB patients were foreign born (44%) and 40% had associ-ated social risk factors (alcoholism being the most prevalent
in 12 cases). HIV testing was reported in 37 (74%) patients—
16 patients with MDR-TB (32%) and four patients with XDR-
TB (33.3%) tested positive. This report found statistical
Table 3 – First- and second-line drug resistance of the MDR-TB (n = 50) patients in the LVT region from 2008 to 2010.
Variables Category Positive cases
Number %
First-line drugs
(any resistance to)
Streptomycin (S) 39 78
Ethambutol (E) 22 44
Pyrazinamide (Z) 35 70
Second-line drugs
(any resistance to)
Amikacin (Am) 7 14
Kanamycin (km) 11 22
Capreomycin (Cm) 12 24
Fluoroquinolones (FQ) 13 26
Ethionamide (Eth) 19 38
p-Aminosalicylic acid (PAS) 1 2
Cycloserine (Cs) 3 6
Linezolid (Lnz) 0 0
Table 4 – Outcomes for the 2008 MDR-TB cohort after 24 months of treatment.
Variables Category MDR-TB n = 22 p Value IC (95%)
XDR-TB
n = 7
Non XDR-TB
n = 15
Outcomes, nr (%) Cured 0 3 (20.0) 0.523 –
Completed 4 (57.1) 5 (33.3) 0.376 0.21 to 0.69
Success 4 (57.1) 8 (53.3) 1.000 0.42 to 0.49
Died 0 0 – –
Default 1 (14.3) 1 (6.7) 1.000 0.22 to 0.37
Transferred out 1 (14.3) 1 (6.7) 1.000 0.22 to 0.37
Still on treatment 1 (14.3) 5 (33.3) 0.616 0.55 to 0.17
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but no significant differences between patients with XDR
and non-XDR-TB (p = 1,000). Being foreign born was also asso-
ciated with the development of MDR-TB (p = 0.015).
The majority of the MDR-TB cases were new cases (70%);
however, the total proportion of MDR-TB cases from 2008 to
2010 was 2.4%, with an incidence of 1.8% amongst new cases
and 9.3% amongst previously treated cases. In fact, retreat-
ment cases were found to be a risk factor for MDR-TB
(p 6 0.0001). Half of the XDR-TB patients were retreatment
cases.
Of the 50 study patients with MDR-TB, an analysis was per-
formed on the first- and second-line drug resistance patterns.
As shown in Table 3, the first-line drugs streptomycin (n = 39,
78%) and pyrazinamide (n = 35, 70%) and the second-line
drugs fluoroquinolones (n = 13, 26%) and ethionamide
(n = 19, 38%) were those with the higher resistance levels.
No resistance to linezolid was found.
In Table 4 the treatment outcomes of the 2008 MDR-TB co-
hort after 24 months of treatment are described. The overall
treatment success for patients with MDR-TB was 54.6% and
for patients with XDR-TB, 57.1%. After 24 months, 27.3% and
14.3% of the MDR and XDR-TB cases, respectively, were clas-
sified as ‘‘still on treatment’’. However, the ‘‘still on treat-
ment’’ cases should be re-classified as ‘‘lost to follow-up’’,
since the surveillance system sorts them as such by defaultif the information is not updated by the clinician at the end
of the treatment.
Discussion
MDR-TB is an increasing global problem, with most cases
arising from a mixture of physician error and patient non-
compliance during treatment of susceptible TB. The extent
and burden of MDR-TB varies significantly from country to
country and region to region. Recent surveillance data,
including data from Portugal, has revealed that the preva-
lence of these drug-resistant cases has risen to the highest
rates ever recorded in its history, and previous drug treatment
is the largest single risk factor for the presence of MDR-TB.
Thus, drug-resistant TB reflects a failure in the implementa-
tion of an effective TB control programme [1,2].
Proper implementation of the DOTS strategy should
achieve a high cure rate for disease and curtail the develop-
ment of drug resistance. Innovations in the expansion of this
strategy should further facilitate its delivery and enhance its
effectiveness. However, established MDR-TB is notoriously
difficult to treat, and it needs the use of alternative specific
anti-tuberculosis chemotherapy regimens. These regimens
comprise a combination use of second-line drugs that are
generally more costly and toxic and have to be given for long-
er periods. The technical key components for a successful
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(1) more accurate and rapid diagnostic methods implementa-
tion, including molecular tests, and regular drug susceptibil-
ity testing; (2) reliable supply of quality treatment regimens
under directly observed settings; and (3) infection control pro-
grammes. The effectiveness of these major points is evalu-
ated with a specific reporting system for MDR-TB cases that
allow the monitoring of the individual treatment outcome
of the patient and the overall performance of the TB control
programme.
In Portugal, the incidence of MDR-TB appears to have been
decreasing, representing an average of 1.5% of the total num-
ber of TB cases in 2009 (1% among new cases and 5.2% in
retreatments). It is comparable to the median of the EU and
is largely confined to the metropolitan areas of Porto and,
mainly, Lisbon. The fact that it is harder to cure and has a
much longer treatment course does increase the number of
prevalent cases. However, in 2007, a national network for
the management of the MDR-TB cases was created [3], and
it may be one of the reasons why these cases have started
to decline steadily. In December 2010, the prevalence of
MDR-TB was 53 cases, 32% of which met the criteria for
XDR, and more than two thirds reside in the LVT region.
Here, this research presented the results of a national sur-
veillance database on clinical, demographic and social-behav-
ioural parameters associated with MDR and XDR-TB in the
population of the LVT region between 2008 and 2010. The
number of MDR-TB cases decreased significantly during this
period: 23 cases in 2008, 16 in 2009 and 11 in 2010. This accen-
tuated decline is corroborated by the DST coverage target,
which remains above 80%, pointed out by WHO for represen-
tativeness to the data [14]. Although the level of multidrug
resistance is not high, MDR-TB is proving to be endemic,
without being restricted to any risk factor, occurs in adults
and children, and in most cases does not have any epidemio-
logical link to other cases (Tables 1 and 2). In fact, its endemic
character is reflected by the proportion of MDR-TB in new
cases—more than 70% of the cases are not related to previous
treatment (of the 50 MDR-TB patients diagnosed, only 30%
had been previously treated for TB). However, the prevalence
amongst retreatment cases—9.3% amongst culture-positive
TB patients—still makes previous treatment one of the major
risk factors known to be associated with the development of
resistance. As shown in Table 1, MDR-TB is closely related
with retreatment cases (p 6 0.0001), HIV positive status
(p = 0.050) and being foreign-born (p = 0.015).
In this cohort, strains of M. tuberculosis in 12 (24%) out of 50
patients with MDR-TB also met the case definition for XDR-
TB. Opposing to most of the alarming reports on the spread
of XDR-TB among HIV-seropositive persons [15], this research
found that HIV co-infection was not related with XDR-TB
(p = 1.00). Also not related with XDR-TB was being foreign-
born (p = 0.512). Previous treatment (p = 0.084) and incarcera-
tion (p = 0.054) were the demographic characteristics more
statistically associated with developing XDR-TB.
This endemic character and the realization that, in many
cases, the therapeutic options are extremely limited have
led to the undertaking of an analysis of the prevalence of
resistance to the various first- and second-line drugs (Table 3).
The major point of this study is the possible definition oftreatment regimens to be applied in patients with high suspi-
cion of MDR-TB or whose MDR-TB was detected using molec-
ular testing without the complete pattern of resistance. In
fact, national guidelines that propose standardized regimens
to be applied on each of the cases were recently published by
the NTP [16,17].
It is known that patients with XDR-TB have a higher risk
for treatment failure or even death than those with MDR-TB
[18,19]. In infections with MDR-TB, drug resistance to addi-
tional first-line drugs other than isoniazid and rifampicin is
related to negative treatment outcomes [20]. Resistance to a
fluoroquinolone and injectable second-line drugs also in-
creases the risk for treatment failure and death in these cases
[21,22] as XDR-TB defining drugs are those considered essen-
tial to achieving successful outcomes in MDR-TB cases [23–
25]. The WHO 2011 report defines as a target over 75% of treat-
ment success for MDR-TB [14]. As shown in Table 4 for the
2008 cohort, which has already completed 24 months of treat-
ment, success rates of 54.6% of the MDR-TB cases and 57.1%
of the XDR-TB cases were achieved. Although it is still some
distance away from the target defined by WHO, it can be con-
sidered relatively good rates compared with some of the re-
cent published studies [18,20,25]. These success rates may
be as a result of the use of linezolid, a third-line anti-TB drug,
to which no resistance was yet reported in the LVT region.
Although it is toxic, it is established that its efficacy and toler-
ability suggest that a linezolid-containing combination treat-
ment might be an effective option against MDR and XDR-TB
cases [24,26]. For this purpose, drug-susceptibility testing for
linezolid is now included in the laboratory routine. However,
to support this fact—that linezolid has a major role in the
treatment of MDR and XDR-TB—other clinical and surveil-
lance studies should be conducted.
In conclusion, it was found that the endemic character of
MDR- and XDR-TB cases may be threatening TB control, and
the major risk factor associated with the increased risk of
developing MDR-TB was, as expected, a previous treatment.
More resources and aggressive TB control efforts are required;
largely through more accurate and rapid drug susceptibility
testing implementation and regular drug-resistance
surveillance.
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